Latest News
News
FDA addresses cell-based regenerative medicine in comprehensive new policy
Clarifying the existing regulations will “promote responsible and flexible regulation that leverages science to advance public health,” according...
Conference Coverage
Prescribers mostly ignore clopidogrel pharmacogenomic profiling
ANAHEIM, CALIF. – Physicians treating ACS patients with an antiplatelet all but ignore their genetically assessed ability to metabolize...
From the Journals
Rituximab key to survival after transplant for mantle cell lymphoma
The benefit of rituximab “stands out, and adds to the increasing body of evidence supporting this practice for all MCL patients after ASCT,...
Conference Coverage
Keep PCI patients on aspirin for noncardiac surgery
ANAHEIM, CALIF. – Perioperative aspirin is more likely to help than harm PCI patients undergoing noncardiac surgery.
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
Conference Coverage
Debate: Is MRD ready for prime time in multiple myeloma?
NEW YORK – Two leading multiple myeloma experts question whether it’s time to incorporate minimal residual disease measures into daily practice....
Conference Coverage
NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancers
Nivolumab has promising activity in mismatch repair–deficient noncolorectal cancers, according to preliminary findings from the NCI-MATCH trial....
Latest News
CRISPR on the Senate health committee menu
From the Journals
Gut bacteria influenced response to checkpoint inhibitors
“An obvious next step is to run a clinical trial to test the hypothesis that by modulating the microbiome, you can actually enhance responses to...
Conference Coverage
VIDEO: U.S. hypertension guidelines reset threshold to 130/80 mm Hg
ANAHEIM, CALIF. – Thirty million Americans became hypertensive overnight.
News
FDA approves dasatinib for pediatric Ph+ CML
Approval was based on complete cytogenetic response data from 97 pediatric patients with chronic phase CML evaluated in two nonrandomized trials...